ICRF-159

Known as: ICI 59118, ICRF 159, ICRF159 
 

Topic mentions per year

Topic mentions per year

1971-2012
051019712012

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1999
1999
A chiral HPLC method has been developed to separate razoxane (ICRF-159) in blood plasma into its enantiomers dexrazoxane (ICRF… (More)
Is this relevant?
1998
1998
To investigate the biochemical properties of individual domains of eukaryotic topoisomerase (topo) II, two truncation mutants of… (More)
Is this relevant?
1997
1997
We have studied the relationship between expression of genes implicated in mediating resistance to cleavable complex-forming… (More)
  • table 1
  • figure 2
  • figure 1
  • figure 3
  • figure 4
Is this relevant?
1995
1995
Bisdioxopiperazines such as ICRF-159 and ICRF-193 have been shown to inhibit DNA topoisomerase II. To determine the molecular… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
1994
1994
Certain bis(2,6-dioxopiperazine) derivatives, which include ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl]propane; ADR-529) and… (More)
Is this relevant?
1982
1982
One hundred and seventy six patients (81 controls, 95 receiving treatment) have entered a prospective randomized tiral of long… (More)
  • table 2
  • table 3
  • table 1
  • table 5
  • table 6
Is this relevant?
1981
1981
We have investigated the effect of ICRF-159 on the toxicity of daunorubicin (DR) and doxorubicin (DX) given iv, and the… (More)
Is this relevant?
1980
1980
This paper describes our experience with the use of razoxane (ICRF 159), a new anti-mitotic drug, in the treatment of thirty-six… (More)
Is this relevant?
1979
1979
Twenty-eight patients with advanced acute nonlymphocytic leukemia, 16 with acute lymphoblastic leukemia, and two with acute… (More)
Is this relevant?
1974
1974
The Walker 256 carcinosarcoma growing in the rat was irradiated with a surface dose of 240 rad on each of three consecutive days… (More)
  • figure I
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?